Rasem Mourad

Array ( [id] => 9280288 [patent_doc_number] => 20140030257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-30 [patent_title] => 'AGTR1 AS A MARKER FOR BEVACIZUMAB COMBINATION THERAPIES' [patent_app_type] => utility [patent_app_number] => 13/911912 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12908 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13911912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12527736 [patent_doc_number] => 10006091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-26 [patent_title] => Method for the diagnosis, prognosis and treatment of lung cancer metastasis [patent_app_type] => utility [patent_app_number] => 14/405724 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 33397 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10254939 [patent_doc_number] => 20150139936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTI-CANCER THERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 14/400223 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10578 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14400223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10416043 [patent_doc_number] => 20150301053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'SURROGATE FUNCTIONAL DIAGNOSTICS TEST FOR CANCER' [patent_app_type] => utility [patent_app_number] => 14/440762 [patent_app_country] => US [patent_app_date] => 2013-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 71 [patent_figures_cnt] => 71 [patent_no_of_words] => 15054 [patent_no_of_claims] => 59 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14440762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989255 [patent_doc_number] => 20130216536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'INHIBITORS OF EXTRACELLULAR HSP90' [patent_app_type] => utility [patent_app_number] => 13/870955 [patent_app_country] => US [patent_app_date] => 2013-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 18851 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13870955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9095004 [patent_doc_number] => 20130274316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'MUC1 AND GALECTIN-3' [patent_app_type] => utility [patent_app_number] => 13/863952 [patent_app_country] => US [patent_app_date] => 2013-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 25798 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13863952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9095005 [patent_doc_number] => 20130274315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'PRO-ANGIOGENIC GENES IN OVARIAN TUMOR ENDOTHELIAL CELL ISOLATES' [patent_app_type] => utility [patent_app_number] => 13/863219 [patent_app_country] => US [patent_app_date] => 2013-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 72841 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13863219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9917144 [patent_doc_number] => 20150072349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'Cancer Biomarkers and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/385449 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 29525 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14385449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11237692 [patent_doc_number] => 09464326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-11 [patent_title] => 'Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance' [patent_app_type] => utility [patent_app_number] => 13/804135 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 39 [patent_no_of_words] => 22649 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13804135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9107148 [patent_doc_number] => 20130280280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'ANTIGEN BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/795314 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 36248 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13795314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864684 [patent_doc_number] => 20150044703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'METHODS AND COMPOSITIONS FOR DETECTING ENDOMETRIAL OR OVARIAN CANCER' [patent_app_type] => utility [patent_app_number] => 14/386285 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20076 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 51 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9107117 [patent_doc_number] => 20130280249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'Directed Engagement Of Activating Fc Receptors' [patent_app_type] => utility [patent_app_number] => 13/794780 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15242 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13794780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10202824 [patent_doc_number] => 20150087812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'Human Autotaxin Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/381227 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 20995 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14381227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9909002 [patent_doc_number] => 20150064203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'ANTICANCER AGENT' [patent_app_type] => utility [patent_app_number] => 14/383118 [patent_app_country] => US [patent_app_date] => 2013-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10440 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14383118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8927537 [patent_doc_number] => 20130183297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-18 [patent_title] => 'METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD' [patent_app_type] => utility [patent_app_number] => 13/776997 [patent_app_country] => US [patent_app_date] => 2013-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18392 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13776997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755996 [patent_doc_number] => 20160102148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME' [patent_app_type] => utility [patent_app_number] => 14/380068 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13871 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8990353 [patent_doc_number] => 20130217634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'PEPTIDES ABLE TO INTERFERE WITH THE INHIBITING ACTIVITY OF MDM2/MDM4 HETERODIMER TOWARDS P53 AND USE THEREOF FOR CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 13/773377 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 7271 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13773377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11231021 [patent_doc_number] => 09458241 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-04 [patent_title] => 'Antibody induced cell membrane wounding' [patent_app_type] => utility [patent_app_number] => 13/770619 [patent_app_country] => US [patent_app_date] => 2013-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 20632 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13770619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9895086 [patent_doc_number] => 20150050285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates' [patent_app_type] => utility [patent_app_number] => 14/372972 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 6803 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14372972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12364248 [patent_doc_number] => 09956276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-01 [patent_title] => Vaccines against antigens involved in therapy resistance and methods of using same [patent_app_type] => utility [patent_app_number] => 14/373103 [patent_app_country] => US [patent_app_date] => 2013-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 8217 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14373103 [rel_patent_id] =>[rel_patent_doc_number] =>)